Want to Join Our Team?
Learn about Blue Matter's innovative work experiences, enriching development opportunities, team-oriented "People First" culture, and a lot more.
Insights
Access our ever-expanding library of thought leadership resources for strategic leaders and professionals in biopharma. It’s full of useful content addressing industry challenges, best practices, therapeutic markets, innovative ideas, and forward-looking insights.
Featured eBook
The “Best Practice Organization” and Its Importance for Success in Today’s Biopharma Industry
Learn More >
Whitepaper
Medical Affairs Metamorphosis, Part III: How Medical Affairs is Becoming a Key Hub for Evidence Generation
Whitepaper
COVID-19’s Impact on the Mental and Behavioral Health Landscape: Two-Year Blip or Permanent Change?
Blog
12 Pitfalls in Europe: Pitfall #11 – Using Individual Preferences vs. Analysis to Select HQ Location
Blog
12 Pitfalls in Europe: Pitfall #10 – Building Like Big Pharma When You’re Not
Blog
Medical Affairs Metamorphosis, Part III: How Medical Affairs is Becoming a Key Hub for Evidence Generation
Blog
COVID-19’s Impact on the Mental and Behavioral Health Landscape: Two-Year Blip or Permanent Change?
Blog
12 Pitfalls in Europe: Pitfall #9 – Missing a Promotable Label
Blog
12 Pitfalls in Europe: Pitfall #8 – Failing to Realize that Early Access Programs (EAPs) Can Boost…or Bite
Whitepaper
Medical Affairs Metamorphosis, Part II – Medical Affairs’ Evolving Role as Insight Generator
Whitepaper
Summary of Blue Matter Breakfast Club #12: How To Build a Great Company Culture Through Effective (Virtual) Engagement
Blog
2022 Firsthand / Vault Ranking Reports for Blue Matter
Blog
12 Pitfalls in Europe: Pitfall #7 – Not Making the Right European Connections
Blog
Medical Affairs Metamorphosis, Part II: Medical Affairs’ Evolving Role as Insight Generator
Blog
12 Pitfalls in Europe: Pitfall #6 – Missing the Mark with Local Health Technology Assessment (HTA)
Whitepaper
Under Pressure: Prescription Digital Therapeutics, a Look at the 2022 US Market Landscape
Blog
Under Pressure: Prescription Digital Therapeutics – How an analysis of the U.S. PDT landscape indicates mounting pressure for a make-or-break next 3 years
